Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy

[1]  James R. Anderson,et al.  Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. , 2019, The Lancet. Oncology.

[2]  C. Huang,et al.  Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers , 2018, Front. Oncol..

[3]  T. Greten,et al.  Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma , 2018, Cancer Immunology, Immunotherapy.

[4]  M. Smid,et al.  Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression. , 2018, Cancer research.

[5]  A. Chiarugi,et al.  Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-γ and TNF-α as Potential Biomarker of Prostate Cancer Progression , 2018, Front. Immunol..

[6]  D. McNeel,et al.  Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer , 2018, Oncotarget.

[7]  D. McNeel,et al.  Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells , 2017, Cancer Immunology Research.

[8]  J. Koopmeiners,et al.  A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). , 2017 .

[9]  D. McNeel,et al.  Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses , 2016, Oncoimmunology.

[10]  D. McNeel,et al.  Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses , 2016, Oncoimmunology.

[11]  D. Munn,et al.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. , 2016, Trends in immunology.

[12]  J. Peterson.  A Cancer Model , 2016 .

[13]  J. Wolchok,et al.  Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. , 2015, Cell reports.

[14]  W. Langridge,et al.  The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity , 2015, Vaccines.

[15]  D. McNeel,et al.  PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope–Modified DNA Vaccine Immunization , 2015, Cancer Immunology Research.

[16]  D. McNeel,et al.  Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[17]  G. Jenster,et al.  Serum kynurenine/tryptophan ratio is not a potential marker for detecting prostate cancer. , 2014, Clinical biochemistry.

[18]  J. Wolchok,et al.  Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 , 2013, The Journal of experimental medicine.

[19]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[20]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[21]  Kazuo Suzuki,et al.  Interferon-γ Regulates the Proliferation and Differentiation of Mesenchymal Stem Cells via Activation of Indoleamine 2,3 Dioxygenase (IDO) , 2011, PloS one.

[22]  T. Leanderson,et al.  Indoleamine 2,3‐dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model , 2010, The Prostate.

[23]  L. Bubendorf,et al.  High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. , 2008, European journal of cancer.

[24]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.

[25]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[26]  E. Werner,et al.  Induction of indoleamine 2,3-dioxygenase in human cells in vitro. , 1991, Advances in experimental medicine and biology.